Foghorn Therapeutics
FHTX
72 hedge funds and large institutions have $227M invested in Foghorn Therapeutics in 2024 Q2 according to their latest regulatory filings, with 16 funds opening new positions, 23 increasing their positions, 16 reducing their positions, and 13 closing their positions.
240% more call options, than puts
Call options by funds: $34K | Put options by funds: $10K
44% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 16
28% more capital invested
Capital invested by funds: $177M → $227M (+$49.4M)
23% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 13
9.13% more ownership
Funds ownership: 62.16% → 71.29% (+9.1%)
4% more funds holding
Funds holding: 69 → 72 (+3)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$31.6M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$22M |
| 3 |
DM
Deerfield Management
New York
|
+$15M |
| 4 |
PA
Perceptive Advisors
New York
|
+$3.24M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$1.72M |
Top Sellers
| 1 |
Invesco
Atlanta,
Georgia
|
-$376K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$256K |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$245K |
| 4 |
Millennium Management
New York
|
-$239K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$190K |
FHTX Hedge Fund Activity: Q2 2024 in Review
72 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Foghorn Therapeutics (FHTX) for Q2 2024, worth a combined $227M — up 28% from $177M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new FHTX positions and 13 closed out — a net gain of 3 holders — while 23 added to existing stakes and 16 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $31.6M. The largest seller was Invesco, exiting entirely with an estimated $376K sold.
- 72 institutional investors held Foghorn Therapeutics (FHTX) as of Q2 2024, up from 69 in Q1 2024.
- Funds reported $227M of Foghorn Therapeutics stock for Q2 2024, up 28% quarter-over-quarter.
- 16 funds opened new Foghorn Therapeutics positions in Q2 2024 and 13 closed out, a net change of +3 holders.
- The largest Foghorn Therapeutics buyer in Q2 2024 was BVF Inc, an estimated $31.6M added.
- The largest Foghorn Therapeutics seller in Q2 2024 was Invesco, an estimated $376K sold.
Based on aggregated 13F filings for Q2 2024.